WIPO and pharma industry launch global medicines patent database
On 25 September, the World Intellectual Property Organisation (WIPO) in collaboration with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) launched the Patent...
World Health Organization Members ask for more time to solve difficult negotiations on access...
World Health Organization member states will propose to continue negotiations on a critical annex to the Pandemic Agreement, after being unable to bridge key...
Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of...
This week various international bodies are tackling different challenges in meeting the urgent problem of scaling-up manufacture of and access to vaccines for Covid-19....
Cystic Fibrosis Medicines Wars in Europe
Monday 4 February, the UK parliament will debate the issuing of a compulsory licence by the government, called ‘Crown use’, for the cystic fibrosis...
New Database Documents the Power of TRIPS Flexibilities
Medicines Law & Policy has published an on-line database of instances of the use of TRIPS flexibilities in public health contexts, titled the TRIPS...
Strong call for transparency on medicine prices, cost of R&D at WHO Fair Pricing...
“Medical innovation has little social value if most people cannot access its benefits…. this is a global human rights issue,” said Mariângela Simão, Assistant...
TRIPS Council to discuss IP and the public interest in the context of Covid-19
The search for new treatments and vaccines needed to respond to the Covid-19 outbreak has laid bare some key issues around intellectual property (IP)...
WHO Fair Pricing Forum: Watching for Drug Industry Accountability
by Katrina Perehudoff and Jennifer Sellin
Expensive medicines are a ubiquitous challenge from which no government is immune. Excessive price hikes are an urgent human...
The Power of TRIPS Flexibilities in Medicines Procurement
The government of Malaysia has began to roll out treatment of people infected with the hepatitis C virus (HCV). Treatment will be a combination of...
The European Commission’s proposal for an EU wide compulsory licensing mechanism
In 2006 the European Generics Association was seeking clarification from the European Commission on whether generic versions of oseltamivir (Tamiflu) could be supplied to...